Trials / Completed
CompletedNCT02071758
Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers
A Phase 1, Open-Label Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-F3 + SLA-SE Vaccine Compared to LEISH-F3 + GLA-SE Vaccine in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Access to Advanced Health Institute (AAHI) · Academic / Other
- Sex
- All
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare the safety, tolerability, and immunogenicity in healthy adult subjects of an investigational vaccine being developed for the prevention of visceral leishmaniasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | LEISH-F3 + SLA-SE | |
| BIOLOGICAL | LEISH-F3 + GLA-SE |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2014-02-26
- Last updated
- 2016-02-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02071758. Inclusion in this directory is not an endorsement.